IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Jonathan W. Ayers sold 26,000 shares of the company’s stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $160.61, for a total value of $4,175,860.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Jonathan W. Ayers also recently made the following trade(s):
- On Wednesday, February 8th, Jonathan W. Ayers sold 36,250 shares of IDEXX Laboratories stock. The stock was sold at an average price of $141.63, for a total value of $5,134,087.50.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up 0.02% on Friday, reaching $161.63. The company’s stock had a trading volume of 470,595 shares. IDEXX Laboratories, Inc. has a 52-week low of $85.98 and a 52-week high of $172.00. The firm has a market capitalization of $14.24 billion, a P/E ratio of 59.89 and a beta of 0.48. The firm has a 50-day moving average price of $159.67 and a 200 day moving average price of $136.46.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Friday, April 28th. The company reported $0.77 EPS for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.16. IDEXX Laboratories had a negative return on equity of 671.57% and a net margin of 12.51%. The company had revenue of $462 million for the quarter, compared to the consensus estimate of $455.10 million. During the same quarter in the previous year, the business earned $0.51 EPS. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. Equities analysts anticipate that IDEXX Laboratories, Inc. will post $3.05 earnings per share for the current fiscal year.
WARNING: This piece was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/05/20/jonathan-w-ayers-sells-26000-shares-of-idexx-laboratories-inc-idxx-stock-updated.html.
Several equities research analysts have recently commented on IDXX shares. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, April 5th. Canaccord Genuity set a $125.00 price objective on IDEXX Laboratories and gave the stock a “buy” rating in a research report on Monday, January 23rd. Stifel Nicolaus increased their price objective on IDEXX Laboratories from $150.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, May 1st. Finally, Feltl & Co. cut IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, February 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $182.00.
Several hedge funds have recently bought and sold shares of IDXX. Bronfman E.L. Rothschild L.P. increased its stake in IDEXX Laboratories by 2.3% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 770 shares of the company’s stock worth $119,000 after buying an additional 17 shares in the last quarter. WFG Advisors LP boosted its position in shares of IDEXX Laboratories by 43.0% in the fourth quarter. WFG Advisors LP now owns 2,918 shares of the company’s stock worth $127,000 after buying an additional 878 shares during the last quarter. Acrospire Investment Management LLC boosted its position in shares of IDEXX Laboratories by 496.5% in the first quarter. Acrospire Investment Management LLC now owns 841 shares of the company’s stock worth $130,000 after buying an additional 700 shares during the last quarter. Global X Management Co. LLC boosted its position in shares of IDEXX Laboratories by 44.6% in the first quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock worth $162,000 after buying an additional 323 shares during the last quarter. Finally, Flagship Harbor Advisors LLC bought a new position in shares of IDEXX Laboratories during the first quarter worth about $200,000. 91.42% of the stock is currently owned by institutional investors.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.